✦ LIBER ✦

8028 Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older

✍ Scribed by Vergote, I.; Vermorken, J.; Pujade-Lauraine, E.; Monk, B.; Lisyanskaya, A.; Rolski, J.; Vasanthan, S.; Santabárbara, P.; Bayever, E.; Poveda, A.

Book ID: 122035265
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71550-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patient-reported outcomes in relapsed ov

Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone

✍ Carolyn N. Krasner; Andres Poveda; Thomas J. Herzog; Jan B. Vermorken; Stanley B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 553 KB

8029 POSTER Health-Related Quality of Li

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

✍ Verqote, I.; Bidzinski, M.; Kelley, J.; Vasanthan, S.; Runnebaum, I.; Vermorken, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB